Publications by authors named "Lily Llorens"

Claim this Profile
E
Efficacy and safety of a 3-day once-daily regimen of oral nafithromycin in comparison to oral moxifloxacin for the treatment of community-acquired bacterial pneumonia in adults: a phase III, randomized, double-blind controlled trial.
Himanshu Pophale, Monica Gupta, Lily Llorens, Piotr Iwanowski, Ranjeet Gutte

Lancet Reg Health Southeast Asia· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinically important change on the Unified Dyskinesia Rating Scale among patients with Parkinson's disease experiencing dyskinesia.
Rajesh Pahwa, Susan Fox, Robert A Hauser, Stuart Isaacson, Judy Lytle, Lily Llorens

Front Neurol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 3, double-blind, placebo-controlled efficacy and safety study of ADS-5102 (Amantadine) extended-release capsules in people with multiple sclerosis and walking impairment.
Jeffrey A Cohen, Michelle H Cameron, Myla D Goldman, Andrew D Goodman, Aaron E Miller, Lily Llorens

Mult Scler· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of ADS-5102 (amantadine) extended release capsules to improve walking in multiple sclerosis: A randomized, placebo-controlled, phase 2 trial.
Jeffrey A Cohen, Samuel F Hunter, Theodore R Brown, Mark Gudesblatt, Ben W Thrower, Lily Llorens

Mult Scler· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Macrolide therapy for community-acquired pneumonia due to atypical pathogens: outcome assessment at an early time point.
Thomas M File, Paul B Eckburg, George H Talbot, Lily Llorens, H David Friedland

Int J Antimicrob Agents· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-Reported Outcome Assessments as Endpoints in Studies in Infectious Diseases.
John H Powers, Kellee Howard, Todd Saretsky, Sarah Clifford, Steve Hoffmann, Lily Llorens

Clin Infect Dis· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program.
John E Mazuski, Leanne B Gasink, Jon Armstrong, Helen Broadhurst, Greg G Stone, Lily Llorens

Clin Infect Dis· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Ceftaroline fosamil versus ceftriaxone for the treatment of community-acquired pneumonia: individual patient data meta-analysis of randomized controlled trials.
Maria Taboada, David Melnick, Joseph P Iaconis, Fang Sun, Nan Shan Zhong, Lily Llorens

J Antimicrob Chemother· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Ceftaroline fosamil versus ceftriaxone for the treatment of community-acquired pneumonia: individual patient data meta-analysis of randomized controlled trials.
Maria Taboada, David Melnick, Joseph P Iaconis, Fang Sun, Nan Shan Zhong, Lily Llorens

J Antimicrob Chemother· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of ceftaroline fosamil for bacteremia associated with community-acquired bacterial pneumonia.
Alena Jandourek, Alexander Smith, Lily Llorens, Dirk A Thye, Paul B Eckburg

Hosp Pract (1995)· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the effect of a supratherapeutic dose of intravenous ceftaroline fosamil on the corrected QT interval.
Todd A Riccobene, Ludmyla Rekeda, Douglas Rank, Lily Llorens

Antimicrob Agents Chemother· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia due to Streptococcus pneumoniae: insights from two randomized trials.
Andrew F Shorr, Marin Kollef, Paul B Eckburg, Lily Llorens, H David Friedland

Diagn Microbiol Infect Dis· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Panton-Valentine leukocidin is not the primary determinant of outcome for Staphylococcus aureus skin infections: evaluation from the CANVAS studies.
Amy Tong, Steven Y C Tong, Yurong Zhang, Supaporn Lamlertthon, Batu K Sharma-Kuinkel, Lily Llorens

PLoS One· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CANVAS 1 and 2: analysis of clinical response at day 3 in two phase 3 trials of ceftaroline fosamil versus vancomycin plus aztreonam in treatment of acute bacterial skin and skin structure infections.
H David Friedland, Tanya O'Neal, Donald Biek, Paul B Eckburg, Douglas R Rank, Lily Llorens

Antimicrob Agents Chemother· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia.
Thomas M File, Donald E Low, Paul B Eckburg, George H Talbot, H David Friedland, Lily Llorens

J Antimicrob Chemother· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia.
Donald E Low, Thomas M File, Paul B Eckburg, George H Talbot, H David Friedland, Lily Llorens

J Antimicrob Chemother· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia.
Thomas M File, Donald E Low, Paul B Eckburg, George H Talbot, H David Friedland, Lily Llorens

Clin Infect Dis· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis